127 related articles for article (PubMed ID: 22484031)
1. Rosuvastatin improves pulse wave reflection by restoring endothelial function.
Ott C; Schneider MP; Schlaich MP; Schmieder RE
Microvasc Res; 2012 Jul; 84(1):60-4. PubMed ID: 22484031
[TBL] [Abstract][Full Text] [Related]
2. Rosuvastatin improves basal nitric oxide activity of the renal vasculature in patients with hypercholesterolemia.
Ott C; Schlaich MP; Schmidt BM; Titze SI; Schäufele T; Schmieder RE
Atherosclerosis; 2008 Feb; 196(2):704-11. PubMed ID: 17298834
[TBL] [Abstract][Full Text] [Related]
3. 25-hydroxyvitamin D insufficiency is associated with impaired renal endothelial function and both are improved with rosuvastatin treatment.
Ott C; Raff U; Schneider MP; Titze SI; Schmieder RE
Clin Res Cardiol; 2013 Apr; 102(4):299-304. PubMed ID: 23262496
[TBL] [Abstract][Full Text] [Related]
4. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia.
Lu TM; Ding YA; Leu HB; Yin WH; Sheu WH; Chu KM
Am J Cardiol; 2004 Jul; 94(2):157-61. PubMed ID: 15246890
[TBL] [Abstract][Full Text] [Related]
5. Rosuvastatin does not affect intrarenal hemodynamics in patients with hypercholesterolemia.
Ott C; Ritt M; Titze SI; Schäufele T; Schmieder RE
J Nephrol; 2009; 22(5):675-81. PubMed ID: 19810001
[TBL] [Abstract][Full Text] [Related]
6. Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients.
John S; Schneider MP; Delles C; Jacobi J; Schmieder RE
Am Heart J; 2005 Mar; 149(3):473. PubMed ID: 15864218
[TBL] [Abstract][Full Text] [Related]
7. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Strandberg TE; Feely J; Sigurdsson EL;
Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
[TBL] [Abstract][Full Text] [Related]
8. Effects of rosuvastatin on 3-nitrotyrosine and aortic stiffness in hypercholesterolemia.
Pirro M; Schillaci G; Mannarino MR; Savarese G; Vaudo G; Siepi D; Paltriccia R; Mannarino E
Nutr Metab Cardiovasc Dis; 2007 Jul; 17(6):436-41. PubMed ID: 17134956
[TBL] [Abstract][Full Text] [Related]
9. C-reactive protein lowering with rosuvastatin in the METEOR study.
Peters SA; Palmer MK; Grobbee DE; Crouse JR; O'Leary DH; Raichlen JS; Bots ML
J Intern Med; 2010 Aug; 268(2):155-61. PubMed ID: 20412373
[TBL] [Abstract][Full Text] [Related]
10. Influence of short-term rosuvastatin therapy on endothelial progenitor cells and endothelial function.
Pirro M; Schillaci G; Romagno PF; Mannarino MR; Bagaglia F; Razzi R; Pasqualini L; Vaudo G; Mannarino E
J Cardiovasc Pharmacol Ther; 2009 Mar; 14(1):14-21. PubMed ID: 19158317
[TBL] [Abstract][Full Text] [Related]
11. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.
Fonseca FA; Ruiz A; Cardona-Muñoz EG; Silva JM; Fuenmayor N; Marotti M;
Curr Med Res Opin; 2005 Aug; 21(8):1307-15. PubMed ID: 16083541
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic interaction between ezetimibe and rosuvastatin.
Kosoglou T; Statkevich P; Yang B; Suresh R; Zhu Y; Boutros T; Maxwell SE; Tiessen R; Cutler DL
Curr Med Res Opin; 2004 Aug; 20(8):1185-95. PubMed ID: 15324521
[TBL] [Abstract][Full Text] [Related]
13. Isoprenoid depletion by statins antagonizes cytokine-induced down-regulation of endothelial nitric oxide expression and increases NO synthase activity in human umbilical vein endothelial cells.
Jantzen F; Könemann S; Wolff B; Barth S; Staudt A; Kroemer HK; Dahm JB; Felix SB; Landsberger M
J Physiol Pharmacol; 2007 Sep; 58(3):503-14. PubMed ID: 17928646
[TBL] [Abstract][Full Text] [Related]
14. Rosuvastatin reduces platelet activation in heart failure: role of NO bioavailability.
Schäfer A; Fraccarollo D; Eigenthaler M; Tas P; Firnschild A; Frantz S; Ertl G; Bauersachs J
Arterioscler Thromb Vasc Biol; 2005 May; 25(5):1071-7. PubMed ID: 15761193
[TBL] [Abstract][Full Text] [Related]
15. Blockade of geranylgeranylation by rosuvastatin upregulates eNOS expression in human venous endothelial cells.
Landsberger M; Jantzen F; Könemann S; Felix SB
Biochem Biophys Res Commun; 2005 Nov; 336(4):1005-9. PubMed ID: 16165089
[TBL] [Abstract][Full Text] [Related]
16. Effects of cerivastatin on forearm vascular responses, blood pressure responsiveness and ambulatory blood pressure in type 2 diabetic men.
Tran D; Lowy A; Howes JB; Howes LG
Diabetes Obes Metab; 2005 May; 7(3):273-81. PubMed ID: 15811145
[TBL] [Abstract][Full Text] [Related]
17. The protective effect of rosuvastatin in human umbilical endothelial cells exposed to constant or intermittent high glucose.
Piconi L; Corgnali M; Da Ros R; Assaloni R; Piliego T; Ceriello A
J Diabetes Complications; 2008; 22(1):38-45. PubMed ID: 18191076
[TBL] [Abstract][Full Text] [Related]
18. Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia.
Kostapanos MS; Milionis HJ; Lagos KG; Rizos CB; Tselepis AD; Elisaf MS
Eur J Pharmacol; 2008 Aug; 590(1-3):327-32. PubMed ID: 18585701
[TBL] [Abstract][Full Text] [Related]
19. Improved endothelial function and reduced platelet activation by chronic HMG-CoA-reductase inhibition with rosuvastatin in rats with streptozotocin-induced diabetes mellitus.
Schäfer A; Fraccarollo D; Vogt C; Flierl U; Hemberger M; Tas P; Ertl G; Bauersachs J
Biochem Pharmacol; 2007 May; 73(9):1367-75. PubMed ID: 17270148
[TBL] [Abstract][Full Text] [Related]
20. Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting.
Bullano MF; Wertz DA; Yang GW; Kamat S; Borok GM; Gandhi S; McDonough KL; Willey VJ
Pharmacotherapy; 2006 Apr; 26(4):469-78. PubMed ID: 16553504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
